Informations générales (source: ClinicalTrials.gov)
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
Interventional
N/A
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
septembre 2024
octobre 2029
02 septembre 2025
The goal of this study is to prospectively follow the level of circulating nucleosomes in
patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the
clinical response.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | David GHEZ | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Histologically proven diagnosis of diffuse large B cell lymphoma or follicular
lymphoma, according to the WHO 2016 classification, requiring a first line of
treatment with a RCHOP 21 regimen
- Agreement to participate after receiving oral and written information on the study
- Histologically proven diagnosis of diffuse large B cell lymphoma or follicular
lymphoma, according to the WHO 2016 classification, requiring a first line of
treatment with a RCHOP 21 regimen
- Agreement to participate after receiving oral and written information on the study
- History of previous treatment for lymphoma (excluding localized low dose
radiotherapy in the case of follicular lymphoma)
- Treatment with a chemotherapy regimen different from RCHOP21